Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIPA solution is a sterile red blood cell rejuvenation processing solution containing sodium pyruvate, inosine, adenine, dibasic sodium phosphate, and monobasic sodium phosphate. The marketed U.S. product is **Rejuvesol**, which is used only extracorporeally: stored red blood cell units are incubated with the solution before washing and transfusion. Its metabolic substrates replenish erythrocyte ATP and 2,3-diphosphoglycerate, helping reverse storage-associated metabolic loss and restore oxygen-release capacity. It is not intended for direct injection into patients. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bc06c40f-81a0-45e5-80b6-61f67d445068))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PIPA solution.